Beta-Lipotropin (1-10), Porcine Mechanisms, Clinical Value,

Beta-Lipotropin (1-10), Porcine: Mechanisms, Clinical Value, and Research Perspectives
Introduction [Related: a 83]
Beta-Lipotropin (1-10), porcine, is a synthetic peptide fragment derived from the N-terminal region of beta-lipotropin, a pro-opiomelanocortin (POMC) cleavage product. Beta-lipotropin itself is a 90-amino acid polypeptide produced primarily in the anterior pituitary and serves as a precursor for several biologically active peptides, including beta-endorphin and melanocyte-stimulating hormones (MSHs) (Li et al., 2016, Peptides). The (1-10) fragment, corresponding to the first ten amino acids of the porcine beta-lipotropin sequence, has garnered interest for its potential neuromodulatory and metabolic effects, as well as its utility as a research tool in neuroendocrinology and peptide signaling studies.
The mechanism of action of Beta-Lipotropin (1-10) is not fully elucidated, but it is believed to interact with specific G protein-coupled receptors (GPCRs) in the central nervous system and peripheral tissues, modulating neurotransmitter release, energy metabolism, and possibly influencing pain perception (Smith & Funder, 1988, Endocrinology). The peptide’s short sequence allows it to serve as a model for studying the structure-activity relationships of POMC-derived peptides and their receptor interactions. [Related: hdac inhibitor tsa]
Clinical Value and Applications [Related: aminopeptidase B]
Beta-Lipotropin (1-10), porcine, is primarily utilized in preclinical research rather than direct clinical therapy. Its value lies in its ability to model the biological activities of endogenous POMC-derived peptides, enabling the dissection of their roles in neuroendocrine regulation, energy homeostasis, and pain modulation.
In neuroscience, Beta-Lipotropin (1-10) is used to investigate the mechanisms underlying opioid peptide signaling, as it shares sequence homology with beta-endorphin, a potent endogenous opioid (Akil et al., 1984, Science). Studies have shown that beta-lipotropin fragments can modulate dopamine release and influence behavioral responses, making them relevant for research into neuropsychiatric disorders and addiction (Kreek et al., 2012, Neuropsychopharmacology).
Additionally, the peptide has been explored for its potential lipolytic effects, given the parent molecule’s historical association with lipid mobilization (Li et al., 2016, Peptides). This has implications for metabolic research, particularly in the context of obesity and metabolic syndrome. Beta-Lipotropin (1-10) also serves as a valuable tool in immunological studies, where POMC-derived peptides are known to modulate immune cell activity (Smith & Funder, 1988, Endocrinology).
Key Challenges and Pain Points Addressed
Current research into neuropeptides and their physiological roles is hampered by the complexity of peptide processing and the overlapping activities of peptide fragments. Beta-Lipotropin (1-10), porcine, addresses several key challenges:
1. **Specificity in Peptide Research:** Full-length POMC and its larger derivatives yield multiple active fragments, complicating the attribution of specific biological effects. The use of well-defined fragments like Beta-Lipotropin (1-10) allows for more precise mapping of structure-function relationships (Li et al., 2016, Peptides).
2. **Modeling Endogenous Peptide Activity:** The peptide provides a simplified model to study the effects of POMC-derived peptides without the confounding influence of longer, multifunctional sequences (Akil et al., 1984, Science).
3. **Receptor Identification and Characterization:** The short sequence facilitates receptor binding studies, aiding in the identification of novel GPCR targets and the development of selective agonists or antagonists (Kreek et al., 2012, Neuropsychopharmacology).
4. **Translational Research:** By elucidating the roles of specific peptide fragments, Beta-Lipotropin (1-10) helps bridge the gap between basic research and therapeutic development, particularly in metabolic and neuropsychiatric disorders.
Literature Review
A growing body of literature supports the utility of Beta-Lipotropin (1-10) and related peptides in biomedical research:
1. **Li et al. (2016, Peptides):** This review highlights the diverse biological activities of POMC-derived peptides, including beta-lipotropin fragments. The authors emphasize the importance of peptide fragments in modulating energy balance and neuroendocrine functions.
2. **Akil et al. (1984, Science):** The study demonstrates the opioid-like activity of beta-endorphin and its precursor peptides, including beta-lipotropin, in the central nervous system. The findings underscore the relevance of short peptide fragments in opioid receptor signaling.
3. **Smith & Funder (1988, Endocrinology):** This work explores the receptor interactions of POMC-derived peptides, noting that short fragments like Beta-Lipotropin (1-10) can exhibit distinct binding profiles and biological effects compared to their parent molecules.
4. **Kreek et al. (2012, Neuropsychopharmacology):** The authors investigate the role of POMC peptides in addiction and stress responses, providing evidence for the involvement of beta-lipotropin fragments in modulating dopaminergic pathways.
5. **Bicknell (2008, Journal of Neuroendocrinology):** This review discusses the processing of POMC and the functional diversity of its peptide products, highlighting the need for fragment-specific studies to unravel their physiological roles.
6. **Hadley & Dallman (1986, Annual Review of Physiology):** The authors provide a comprehensive overview of pituitary peptide hormones, including beta-lipotropin, and their effects on lipid metabolism and neuroendocrine regulation.
7. **Mains et al. (1977, Proceedings of the National Academy of Sciences):** This seminal paper describes the biosynthesis and processing of POMC, laying the groundwork for subsequent studies on the biological activities of its peptide fragments.
Experimental Data and Results
Experimental studies utilizing Beta-Lipotropin (1-10), porcine, have focused on its neuropharmacological and metabolic effects in animal models and in vitro systems.
**Neuropharmacological Effects:** In rodent models, intracerebroventricular administration of Beta-Lipotropin (1-10) has been shown to modulate locomotor activity and alter pain thresholds, suggesting partial agonist activity at opioid receptors (Akil et al., 1984, Science). Electrophysiological studies indicate that the peptide can influence synaptic transmission in the hypothalamus, a key site for energy homeostasis and neuroendocrine integration (Li et al., 2016, Peptides).
**Metabolic Effects:** While the full-length beta-lipotropin is associated with lipolytic activity, the (1-10) fragment’s effects on adipose tissue and lipid metabolism are less pronounced but still detectable in vitro. Some studies report modest increases in lipolysis and fatty acid mobilization in adipocyte cultures treated with the peptide (Hadley & Dallman, 1986, Annual Review of Physiology).
**Receptor Binding Studies:** Radioligand binding assays have demonstrated that Beta-Lipotropin (1-10) can bind to specific GPCRs in brain tissue, albeit with lower affinity than longer POMC-derived peptides. This supports its use as a tool for mapping receptor-ligand interactions and for screening novel modulators of peptide signaling (Smith & Funder, 1988, Endocrinology).
**Immunomodulatory Activity:** Preliminary data suggest that Beta-Lipotropin (1-10) may influence cytokine production in immune cell cultures, though these effects are less well-characterized and require further investigation (Bicknell, 2008, Journal of Neuroendocrinology).
Usage Guidelines and Best Practices
Beta-Lipotropin (1-10), porcine, is supplied as a synthetic peptide, typically in lyophilized powder form. The following guidelines are recommended for its use in research settings:
1. **Reconstitution:** The peptide should be reconstituted in sterile, distilled water or appropriate buffer (e.g., phosphate-buffered saline) to the desired concentration. For in vitro studies, concentrations typically range from 0.1 to 10 μM, depending on the assay.
2. **Storage:** Aliquots of reconstituted peptide should be stored at -20°C or lower to maintain stability. Avoid repeated freeze-thaw cycles.
3. **Administration:** For in vivo studies, administration routes include intracerebroventricular, intraperitoneal, or subcutaneous injection, with dosing regimens tailored to the experimental model. Dose-response studies are recommended to determine optimal concentrations and minimize off-target effects.
4. **Controls:** Use of appropriate negative controls (e.g., vehicle-treated or scrambled peptide) is essential to validate the specificity of observed effects.
5. **Safety:** While Beta-Lipotropin (1-10) is considered low-risk in laboratory Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 33 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11567666